Technical Analysis for OPTN - OptiNose, Inc.

Grade Last Price % Change Price Change
D 1.05 0.96% 0.01
OPTN closed up 0.96 percent on Monday, July 1, 2024, on 83 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.96%
Fell Below 50 DMA Bearish 0.96%
180 Bearish Setup Bearish Swing Setup 0.96%
Volume Surge Other 0.96%
Oversold Stochastic Weakness 0.96%
Crossed Above 50 DMA Bullish -2.78%
Stochastic Buy Signal Bullish -2.78%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 6 hours ago
60 Minute Opening Range Breakdown about 8 hours ago
50 DMA Resistance about 9 hours ago
Up 3% about 9 hours ago
Up 2% about 9 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical Disease Organ Systems Inflammation Allergy Respiratory Therapy Polyp Sinus Glucocorticoids Chronic Rhinosinusitis Corticosteroid Nasal Spray Sinusitis Fluticasone Nasal Polyps

Is OPTN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.1
52 Week Low 0.8
Average Volume 1,459,460
200-Day Moving Average 1.27
50-Day Moving Average 1.08
20-Day Moving Average 1.11
10-Day Moving Average 1.08
Average True Range 0.09
RSI (14) 44.75
ADX 17.16
+DI 20.51
-DI 14.40
Chandelier Exit (Long, 3 ATRs) 1.06
Chandelier Exit (Short, 3 ATRs) 1.26
Upper Bollinger Bands 1.25
Lower Bollinger Band 0.97
Percent B (%b) 0.29
BandWidth 25.55
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0111
Fundamentals Value
Market Cap 117.93 Million
Num Shares 112 Million
EPS -0.38
Price-to-Earnings (P/E) Ratio -2.76
Price-to-Sales 2.09
Price-to-Book 24.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.13
Resistance 3 (R3) 1.13 1.10 1.11
Resistance 2 (R2) 1.10 1.08 1.10 1.11
Resistance 1 (R1) 1.08 1.07 1.09 1.08 1.10
Pivot Point 1.05 1.05 1.06 1.05 1.05
Support 1 (S1) 1.03 1.03 1.04 1.03 1.00
Support 2 (S2) 1.00 1.02 1.00 0.99
Support 3 (S3) 0.98 1.00 0.99
Support 4 (S4) 0.98